Avani Athauda, MBBS, MRCP, The Royal Marsden NHS Foundation Trust, London, UK, presents results of an interim safety analysis of 15 patients from the ongoing ICONIC study (NCT03399071), a single-arm Phase II trial investigating the safety and efficacy of periperative FLOT in combination with avelumab, an anti-PD-L1 antibody in patients with resectable esophagogastric adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
24 окт 2024